Data / Drug companies / SpecGx LLC
SpecGx LLC: 229 products in the FDA NDC directory, labeler code 0406
SpecGx LLC (labeler code 0406) lists 229 products in the FDA National Drug Code Directory, covering 22 finished drugs by generic name. By type: 126 prescription drugs, 82 bulk ingredients. Its main marketing category is generic drugs (ANDA). The newest product started marketing on January 19, 2026.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 0406
- Products in commercial distribution
- 229
- Packages
- 482
- Finished drugs by generic name
- 22
- Prescription products
- 126
- Over the counter products
- 0
- Controlled substance products
- Schedule II 140, Schedule III 12, Schedule IV 8, Schedule V 2
- Flagged as original packager
- 101 of 101 products that carry the flag
- Started marketing in the last 12 months
- 2
- Products with a marketing end date set
- 7
- Earliest marketing start
- March 14, 1973
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 104 | 45.4% |
| Bulk ingredients | 80 | 34.9% |
| New drug applications (NDA) | 20 | 8.7% |
| Drugs for further processing | 18 | 7.9% |
| Export only | 3 | 1.3% |
| Bulk ingredients for compounding | 2 | 0.9% |
| Authorized generics (NDA) | 2 | 0.9% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 126 | 55% |
| Bulk ingredients | 82 | 35.8% |
| Drugs for further processing | 21 | 9.2% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Powder | 99 | 43.2% |
| Tablet | 48 | 21% |
| Capsule | 25 | 10.9% |
| Capsule, extended release | 19 | 8.3% |
| Tablet, extended release | 10 | 4.4% |
| Patch, extended release | 7 | 3.1% |
| Tablet, chewable | 6 | 2.6% |
| Solution | 5 | 2.2% |
| Concentrate | 3 | 1.3% |
| Tablet, film coated | 3 | 1.3% |
| Capsule, gelatin coated | 2 | 0.9% |
| Liquid | 1 | 0.4% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Buprenorphine HCl | 0406-7018 | Tablet | Generic drugs (ANDA) | January 19, 2026 |
| Buprenorphine HCl | 0406-7012 | Tablet | Generic drugs (ANDA) | January 19, 2026 |
| Dextroamphetamine sulfate fine np | 0406-9451 | Powder | Bulk ingredients | August 28, 2025 |
| Dextroamphetamine sulfate np | 0406-9450 | Powder | Bulk ingredients | August 28, 2025 |
| Dextroamphetamine saccharate fine np | 0406-9440 | Powder | Bulk ingredients | August 28, 2025 |
| Dextroamphetamine saccharate np | 0406-9401 | Powder | Bulk ingredients | August 28, 2025 |
| Prucalopride | 0406-6302 | Tablet, film coated | Generic drugs (ANDA) | June 24, 2025 |
| Prucalopride | 0406-6301 | Tablet, film coated | Generic drugs (ANDA) | June 24, 2025 |
| Dextromethadone hydrochloride | 0406-8534 | Powder | Bulk ingredients | January 1, 2025 |
| Dextromethadone hydrochloride | 0406-8514 | Powder | Bulk ingredients | January 1, 2025 |
| Lisdexamfetamine Dimesylate | 0406-5129 | Tablet, chewable | Generic drugs (ANDA) | December 17, 2024 |
| Lisdexamfetamine Dimesylate | 0406-5128 | Tablet, chewable | Generic drugs (ANDA) | December 17, 2024 |
| Lisdexamfetamine Dimesylate | 0406-5127 | Tablet, chewable | Generic drugs (ANDA) | December 17, 2024 |
| Lisdexamfetamine Dimesylate | 0406-5126 | Tablet, chewable | Generic drugs (ANDA) | December 17, 2024 |
| Lisdexamfetamine Dimesylate | 0406-5125 | Tablet, chewable | Generic drugs (ANDA) | December 17, 2024 |
| Lisdexamfetamine Dimesylate | 0406-5124 | Tablet, chewable | Generic drugs (ANDA) | December 17, 2024 |
| Lubiprostone | 0406-6424 | Capsule, gelatin coated | Authorized generics (NDA) | May 1, 2024 |
| Lubiprostone | 0406-6408 | Capsule, gelatin coated | Authorized generics (NDA) | May 1, 2024 |
| Mixed Salts of a Single-Entity Amphetamine Product | 0406-0807 | Capsule, extended release | Generic drugs (ANDA) | November 1, 2023 |
| Mixed Salts of a Single-Entity Amphetamine Product | 0406-0805 | Capsule, extended release | Generic drugs (ANDA) | November 1, 2023 |
| Mixed Salts of a Single-Entity Amphetamine Product | 0406-0804 | Capsule, extended release | Generic drugs (ANDA) | November 1, 2023 |
| Mixed Salts of a Single-Entity Amphetamine Product | 0406-0803 | Capsule, extended release | Generic drugs (ANDA) | November 1, 2023 |
| Morphine Sulfate | 0406-5119 | Tablet | Generic drugs (ANDA) | September 1, 2023 |
| Morphine Sulfate | 0406-5118 | Tablet | Generic drugs (ANDA) | September 1, 2023 |
| Lisdexamfetamine Dimesylate | 0406-5117 | Capsule | Generic drugs (ANDA) | August 25, 2023 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.